U.S. Industrial REITs Stock News

Wondering whether Versant Media Group at around US$38.74 is a bargain or just fairly priced? This article walks through what that share price could imply about the company's current value. The stock has been volatile recently, with a 5.2% drop over the last 7 days, a 9.3% gain over the last 30 days, and a 17.0% decline year to date, which may signal changing views on both upside potential and risk. Recent coverage around Versant Media Group has focused on its position within the media sector...

Ames National (ATLO) opened Q1 2026 with total revenue of US$18.6 million and basic EPS of US$0.67, with trailing twelve month revenue at US$69.1 million and EPS at US$2.43 framing the latest quarter in a wider earnings context. Over the past year, revenue has moved from US$53.5 million to US$69.1 million on a trailing basis while EPS has gone from US$1.14 to US$2.43, indicating a business that has been scaling its earnings faster than its top line. Together with a trailing net profit margin...

Penumbra, Inc. recently reported 90-day results from its STORM-PE randomized trial, showing that computer assisted vacuum thrombectomy plus anticoagulation produced greater functional improvement and comparable safety versus anticoagulation alone in acute intermediate-high risk pulmonary embolism, based on data presented at the Society of Interventional Radiology Annual Scientific Meeting. The trial’s first-of-its-kind data, alongside ongoing STRIKE-PE real-world outcomes research, positions...

If you are wondering whether Four Corners Property Trust is attractively priced at around US$25.43, the next step is to look past the headline share price and focus on what the underlying numbers suggest about value. The stock has been relatively calm over the last week with a 0.9% decline. However, the 7.3% return over 30 days and 9.4% return year to date, set against a 2.7% decline over the last year, gives mixed signals about how the market is currently viewing it. This article was...

WaterBridge Infrastructure (NYSE:WBI) has appointed Valerie Chase as an independent director. Chase will also serve as Chair of the Audit Committee, bringing extensive public company finance experience. The appointment adds further expertise to board oversight and financial reporting processes. For investors watching NYSE:WBI, this board change comes as the stock trades at $28.47, with a return of 44.4% year to date and 13.2% over the past week. Those figures may put governance moves like...

Las Vegas Sands (LVS) has opened Q1 2026 with total revenue of US$3.6 billion and basic EPS of US$0.85, setting the tone for how the year is starting to shape up against already improved profitability. Over the past five quarters, the company has seen revenue move from US$2.9 billion in Q4 2024 to between US$2.9 billion and US$3.6 billion through 2025 into Q1 2026, while quarterly EPS has ranged from US$0.45 to US$0.85. This reflects the earnings growth that underpins the trailing 12 month...

If you are wondering whether Target Hospitality's current share price lines up with its underlying worth, the recent trading history gives you plenty to think about. The stock last closed at US$14.25, with a 4.0% decline over the past week contrasted against gains of 48.3% over 30 days, 75.9% year to date, and 124.4% over the last year. This mix of short-term weakness and longer-term strength can change how the market views both its potential and its risks. Recent coverage has focused on...

Polibeli Group's FY 2025 Earnings Snapshot Polibeli Group (NasdaqGM:PLBL) has reported its latest figures with trailing twelve month revenue of about US$26.4 million and a loss of US$5.97 million, translating to a basic EPS of US$0.016, alongside reported revenue growth of 32.6% over the past year. The company has seen revenue move from US$22.8 million in the twelve months to the second half of 2023 to US$26.4 million in the latest trailing period, while basic EPS moved from US$0.013 to...

Rithm Property Trust (RPT) opened Q1 2026 with total revenue of US$2.9 million and basic EPS of US$0.43 loss per share, giving investors a fresh look at how the business is tracking after a volatile 2025. Over the past year, revenue has moved from US$18.3 million on a trailing basis in Q4 2025 to US$22.0 million by Q1 2026, while trailing twelve month EPS has shifted from a US$0.36 loss to a US$0.30 loss. With the share price around US$14.43, the latest release puts the spotlight squarely on...

Investors may be wondering whether Monolithic Power Systems at around US$1,632 per share is still offering value, or if expectations are already fully priced in. The stock has posted returns of 11.1% over the last 7 days, 54.2% over the last 30 days, 74.3% year to date and 181.7% over the past year, with longer term returns of 261.4% over 3 years and 368.4% over 5 years. These strong price moves have kept Monolithic Power Systems firmly on investors' watchlists, as the market reacts to...

Wealthfront (WLTH) closed FY 2026 with Q4 revenue of US$96.1 million and a basic EPS loss of US$1.30, alongside trailing 12 month revenue of US$365.0 million and a trailing basic EPS loss of US$0.74. Over the past six quarters, the company has seen quarterly revenue move from US$80.3 million in Q3 2025 to US$96.1 million in Q4 2026. Basic EPS has shifted from US$0.77 in Q3 2025 to US$0.72, US$0.86 and US$0.75 in the first three quarters of 2026 before turning to a loss of US$1.30 in Q4 2026...

Wondering if Opera's recent share price puts it in the bargain bin or the overhyped aisle? This article breaks down what the numbers say about value. At a last close of US$17.23, Opera's share price comes with recent returns of 0.6% over 7 days, 25.6% over 30 days, 21.1% year to date, 16.3% over 1 year, 67.0% over 3 years, and 105.9% over 5 years. These moves sit against a backdrop of ongoing interest in Opera as a software name, with headlines frequently focusing on its role as a browser...

Wondering whether Palvella Therapeutics at around US$123.59 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price could mean for you. The stock has seen a 23.2% return year to date and a 386.8% return over the last year, alongside shorter term moves of a 2.7% return over 30 days and a 4.9% decline over the past week. Recent attention on Palvella Therapeutics has centered on how the market is reassessing smaller biotech names...

If you are wondering whether Ciena's current share price reflects its true worth, the recent trading history gives you plenty to think about. The stock last closed at US$520.80, with returns of 2.6% over 7 days, 19.0% over 30 days and 111.7% year to date, plus very large returns over 1 year and the past 3 and 5 years. Recent coverage has focused on Ciena as a key player in communications technology, with attention on how its products fit into growing data and network demand. This context has...

If you are wondering whether Wintrust Financial at US$147.91 still offers value or is starting to look stretched, the recent share price and fundamentals give you some clear clues to work with. The stock has held up over the last week with a 0.2% decline. The 30 day return sits at 8.0% and the 1 year return at 35.6%, with longer term returns of 128.2% over 3 years and 108.7% over 5 years. Recent coverage has focused on Wintrust Financial as part of broader discussions around US regional...

FDA extends Priority Review for Savara’s molgramostim BLA in autoimmune PAP by three months following a major amendment. Regulator cites no new safety, efficacy, or manufacturing concerns in connection with the extension. Extension reflects ongoing review activity for Savara’s lead product candidate, ticker NasdaqGS:SVRA. Savara, listed on NasdaqGS:SVRA, focuses on therapies for rare respiratory diseases, with molgramostim as its most advanced program targeting autoimmune pulmonary alveolar...

If you are wondering whether ANI Pharmaceuticals at around US$78.64 is priced attractively or already reflects a lot of optimism, the starting point is to understand what the current share price implies about future expectations. The stock shows mixed recent returns, with a 2.8% decline over 7 days, a 6.2% gain over 30 days, a 0.3% return year to date, 12.6% over 1 year, 108.5% over 3 years and 136.3% over 5 years. Recent coverage around ANI Pharmaceuticals has focused on its position within...

If you are wondering whether TransMedics Group at around US$110.93 is still priced attractively or already baking in a lot of optimism, this article walks through the key valuation clues. The stock has had a mixed recent run, with a 4.3% pullback over the last 7 days, an 8.5% gain over 30 days, a 9.6% decline year to date, an 18.6% return over the past year, and a very large 3 year gain of around 40.2%. Recent headlines around TransMedics Group have continued to focus on its position in the...

Wondering if Axsome Therapeutics at around US$185.96 is offering fair value or stretching expectations? This breakdown will help you frame what the current price might be implying. The stock has seen a 14.9% return over the last 30 days and a 75.0% return over the last year. The year to date return sits at 4.1%, while the 7 day return is a 1.6% decline. Recent headlines around Axsome have focused on the company as a higher profile name within pharmaceuticals and biotech. This helps explain...

Instacart, listed as NasdaqGS:CART under Maplebear, has announced the acquisition of Instaleap. Instaleap operates a fulfillment and enablement platform across roughly 30 countries outside North America. The deal is intended to expand Instacart's enterprise services across Europe, Latin America, and the Middle East. Instacart's parent company Maplebear, trading at $42.17, is adding Instaleap to widen its international reach beyond its core North American base. The move comes after a 15.9%...

Verisk Analytics (NasdaqGS:VRSK) has agreed to acquire AccuLynx, a SaaS provider in the restoration and repair industry, in a pending US$2.35b deal. The company expects the transaction to support its property estimating solutions and to be accretive by the end of 2026. Recent collaborations include integrations with Roofr Inc. for insurance claim processing and Pilotbird for social media investigative reports. These moves expand Verisk's ecosystem for insurance and claims professionals...

Activist investor Land & Buildings has criticized Welltower's new executive compensation plan, describing it as unusually aggressive. The investor argues the structure could work against shareholder interests and weaken alignment between management and owners. The dispute focuses on governance and incentives at NYSE:WELL, rather than short term operating performance. For investors watching NYSE:WELL, this governance debate arrives with the shares at $208.75 and with very large longer term...

If you are wondering whether Boston Scientific at around US$62 a share is starting to look appealing on value, or if the price still has more to adjust, this article is for you. The stock has seen a 3.4% decline over the last week, an 11.0% decline over the last month, and year to date is down 34.5% with a 39.1% decline over the last year, even though the 3 year and 5 year returns sit at 19.1% and 42.4% respectively. Recent moves are playing out against a backdrop of ongoing interest in...

Maze Therapeutics (NasdaqGM:MAZE) completed a sizable underwritten public offering of common stock and pre funded warrants. The deal drew significant participation from both new and existing institutional investors. Proceeds are earmarked to advance Maze Therapeutics' research and development programs focused on serious diseases. Maze Therapeutics, trading at a recent share price of $25.81, has experienced sharp share price swings, with a 7 day return of an 8.1% decline and a 30 day return...